Alkem Medtech Private Limited, Alkem Laboratories’ wholly-owned Indian subsidiary, has executed a Share Purchase Agreement (SPA) for the acquisition of M/s. Occlutech Holding AG, a Swiss-incorporated company. The transaction aims for Alkem Medtech to acquire between 51% and 55% of Occlutech’s total issued equity share capital. This key development follows the initial intimation made on February 13th, 2026, formalizing the path for increased ownership in the Swiss entity.
Update on Major Acquisition Activity
This formal disclosure confirms a significant step forward in Alkem Laboratories’ strategic expansion plans. On March 6th, 2026, the Company’s wholly owned subsidiary, Alkem Medtech Private Limited, executed the necessary Share Purchase Agreement (SPA) concerning the acquisition of Occlutech Holding AG. Occlutech is a company incorporated in Switzerland.
Targeted Stake in Occlutech
The transaction is targeted at securing a substantial controlling interest in the Swiss entity. Alkem Medtech intends to acquire a minimum of 51% and a maximum of 55% of the total issued equity share capital of Occlutech. This action follows the original intent announced to the exchanges on February 13th, 2026.
Formal Compliance and Next Steps
The execution of the SPA with the selling shareholders of Occlutech marks the formalization of the deal structure. The Company confirmed that a copy of this formal disclosure will be made publicly available on its official website in adherence to relevant corporate regulations.
Source: BSE
